O007/#456 Post-hoc analysis of objective response rate by mismatch repair protein dimer loss/mutation status in patients with mismatch repair deficient endometrial cancer treated with dostarlimab
- Resource Type
- Source
- Oral Abstracts (Regular and Late-Breaking Submission).
- Subject
- Language